ORION CORPORATION
STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
21 March 2023 at 17:45 EET
Orion Corporation: Charman of the Nomination Committee changes
After being elected as Chairman of the Board of Directors of Oriola Corporation the Chairman of the Nomination Committee of Orion Corporation Heikki Westerlund has resigned from the Nomination Committee of Orion Corporation. The Board of Directors of Orion Corporation has appointed Timo Maasilta as the new Chairman of the company's Nomination Committee.
Composition of the Nomination Committee is:
- Timo Maasilta, Chairman
- Annika Ekman
- Petteri Karttunen
- Hilpi Rautelin
- Mikael Silvennoinen
Orion Corporation
| Liisa Hurme President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Liisa Hurme, President and CEO
tel. +358 10 426 2874
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
